The impact of statin treatment on diabetic patients.
Retrospective analysis of secondary prevention trials indicates that 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors (statins) reduce the risk of recurrent coronary heart disease events in individuals with diabetes. Diabetic individuals may receive greater benefit from statin treatment than non-diabetic individuals, because of a higher absolute risk. Available data are limited, although several randomized trials of primary prevention with diabetic patients are ongoing. The low-density lipoprotein cholesterol goal is now considered to be < 100 mg/dl for individuals with diabetes. Pleiotropic effects of statins may be involved in anti-atherogenic or other actions of statin.